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Objectives: Differences in the process of using liver imaging technologies might be important to patients. This study aimed to investigate preferences for scanning modalities used in
diagnosing focal liver lesions.
Methods: A discrete choice experiment was administered to 504 adults aged25 years. Respondents made repeated choices between two hypothetical scans, described according
to waiting time for scan and results, procedure type, the chance of minor side-effects, and whether further scanning procedures were likely to be required. Choice data were analyzed
using mixed-logit models with respondent characteristics used to explain preference heterogeneity.
Results: Respondents preferred shorter waiting times, the procedure to be undertaken with a handheld scanner on a couch instead of within a body scanner, no side-effects, and no
follow–up scans (p .01). The average respondent was willing to wait an additional 2 weeks for the scan if it resulted in avoiding side-effects, 1.5 weeks to avoid further
procedures or to be told the results immediately, and 1 week to have the scan performed on a couch with a handheld scanner. However, substantial heterogeneity was observed in
the strength of preference for desirable imaging characteristics.
Conclusions: An average individual belonging to a general population sub–group most likely to require imaging to characterize focal liver lesions in the United Kingdom would prefer
contrast–enhanced ultrasound over magnetic resonance imaging or computed tomography. Insights into the patient perspective around differential characteristics of imaging
modalities have the potential to be used to guide recommendations around the use of these technologies.
Imaging is an important intervention to support diagnosis, plan-
ning and ongoing surveillance in people with suspected or con-
firmed liver disease. An array of imaging modalities is now
available to investigate and characterize focal liver lesions prin-
cipally to distinguish between malignant and benign lesions not
requiring further treatment (1). Techniques available include
ultrasound (US), computed tomography (CT), and magnetic
resonance imaging (MRI) with or without a contrast agent en-
hancement. There is a need for guidance on the comparative
benefits, costs and place of these different modalities in the
diagnostic pathway (1–3).
Contrast–enhanced ultrasound (CEUS) has been reported
to have good overall sensitivity and specificity in the diagnostic
work-up of focal liver lesions in most indications and to be a
cost–effective alternative to contrast–enhanced CT or MRI (4).
The United Kingdom (UK) National Institute for Health and
Care Excellence (NICE) recently issued diagnostics guidance
on the use of SonoVue R© contrast agent (sulphur hexafluoride
microbubbles) for CEUS imaging of the liver (1). CEUS us-
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ing SonoVue R© contrast agent has been shown to accurately
discriminate between malignant and benign focal liver lesions
(5) and characterize focal liver lesions (6;7) and liver metas-
tases (8). Moreover, reports of serious adverse reactions to the
SonoVue R© contrast agent are very rare (9;10).
The NICE diagnostics guidance recommends SonoVue R©
CEUS for the characterization of incidentally detected focal
liver lesions in adults where an earlier unenhanced ultrasound
was inconclusive. It is also recommended for patients undergo-
ing surveillance for cirrhosis ormetastatic disease and forwhom
contrast–enhanced CT or MRI is not clinically appropriate, ac-
cessible or acceptable and an unenhanced US scan is unsatis-
factory or inconclusive and where a contrast agent is required
for further diagnosis (1). The NICE recommendation was made
following a review of the comparative clinical and economic
evidence suggesting CEUS to be a cost–effective alternative to
contrast–enhanced CT orMRI (1). However, evidence reporting
on patient preferences for CEUS compared with other imaging
modalities is limited, leading to NICE recommending further
research in this area (1).
Regardless of any difference in health and economic out-
comes, there are differences in the process of using CEUS,
CE-MRI, and CE-CT which might be important to patients.
Advantages associated with CEUS include the availability of
immediate results, low risk of serious adverse effects, and the
avoidance of ionizing radiation (3;4). However, there is an
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increased risk of follow–up scans in selected patient groups
(11). There is limited evidence documenting which component
of the imaging process (CE-CT, CE-MRI, and CEUS) affects
patients’ experience, or the extent to which patients would be
willing to trade between these different imaging characteristics.
Literature exploring the patient experience of CT and MRI
is less sparse and the side effects (claustrophobia, anxiety) of
these scanningmodalities are well documented (12;13). A study
investigating patient preferences for receiving radiology results
(CT and US) concluded that patients preferred hearing results
from their ordering provider or consultant radiologist with anx-
iety decreasing after consultation (14). In a further study, which
interviewed UK clinicians, it was observed that they expected
patients to prefer ultrasound compared with CT or MRI, due to
it being the more patient–friendly, and the fact that scan results
are given to patients in 80–90 percent of cases on the same day
(15). No research specifically investigating patient experience
of or preferences for CEUS has been identified.
Although the NICE guidance (1) research recommenda-
tions refer to more than one scanning modality patients are
unlikely to experience more than two scanning modalities in the
UK health service system (15) for the same medical condition.
One approach that can be used to capture preference of the three
imaging modalities, using hypothetical scenarios, is a discrete
choice experiment (DCE). The DCE has its foundations in ran-
dom utility and consumer choice theories (16), and has become
popular as a method to evaluate stated preferences for health-
care interventions and services (17). It allows an assessment of
the trade–offs individuals would make between different char-
acteristics of an intervention and of the comparative value and
priority given to interventions from the consumers’ perspective.
DCEs have been used to elicit patient preferences for choice of
diagnostic tests (18), and scanning modalities (19). To-date, the
DCE approach has not been used to measure patient preferences
for scanning modalities in the context of liver disease.
This article reports a DCE investigating preferences for
scanning modalities used in diagnosing focal liver lesions.
The study adds to our existing understanding by focusing on
preferences for the characteristics of three specific imaging
modalities (CEUS, CE-MRI, and CE-CT) that have not pre-
viously been compared, to ascertain preferences for scanning
modalities including CEUS which has been recommended
in recent NICE guidance (1). The study aimed to determine
these preferences in a population similar in characteristics to
those most likely to undergo imaging to characterize focal liver
lesions. This population was matched as closely as possible to
the demographics of patients with liver conditions (cirrhosis
and cancer) in the UK (20). Specifically, the study focuses
on how preferences vary with waiting time (for scan), time
to results (after scan), type of procedure, side effects, and the
likelihood further procedures are necessary. It was intended
that the results would inform the review and recommendations
made in the NICE guideline (1) update.
METHODS
In a DCE, respondents are presented with a series of choices
between two or more alternatives, and are asked to select the
alternative they prefer in each choice set. Each alternative is
described according to a combination of attributes and levels.
The levels of the attributes are varied systematically across the
alternatives. The relative importance of the attributes and the
trade-offs individuals make when choosing one alternative over
another are estimated through regression analysis of the choice
data.
DCE Attributes and Levels
The first stage in developing a DCE involves the identification
and selection of the attributes and levels used to describe the
alternatives in the choice set. In developing the attributes and
levels for the DCE use was made of the NICE Guidance (Di-
agnostics Guidance [DG]) (5) to identify pathways, diagnostic
and referral processes associated with the scanning modalities
(1). Furthermore, a targeted review of the literature was un-
dertaken to identify issues and concerns of patients undergoing
scans (e.g., claustrophobia, adverse events). Both of these were
used to develop a set of questions which were used to guide
semi–structured interviews with UK clinicians (radiologists or
sonographers, n = 7) which provided an overview of clinical
practice and patient pathways, as well as detailing the clini-
cians’ views on patients’ experience of the process (15).
The NICE guidance, literature review and clinician inter-
views were used to develop a patient experience questionnaire
completed by 40 patients attending the Leeds St James’s Univer-
sity Hospital clinic for CEUS to capture patients’ perceptions
of the (dis)advantages of the imaging modalities; to confirm if
the clinicians’ views of patient experiences were accurate and
to draw out any experiences or side effects that had not been
identified from the clinician interviews to finalize development
of the attributes and levels. The final attributes and levels for
the DCE choice sets are described in Table 1. The DCE also
included questions related to respondents’ socio-demographic
characteristics, health status, and previous experience with the
imaging modalities in general. The Short Form Health Survey
12 (SF-12) was also included in the DCE (21). The SF-6D may
be derived from the SF-12 to provide a preference-based single
index measure of health (22).
The DCE was piloted in a convenience sample (n = 20) to
confirm the face validity of the task before being administered
to respondents.
Experimental Design
The attribute levels shown in Table 1 can be combined into
1,128 (i.e., (3∗(2ˆ4))∗(3∗(2ˆ4)-1)/2) different pairs of alterna-
tive scans. Therefore, statistical design theory was used to select
the specific combinations of attributes and levels to be pre-
sented as alternatives in several choice sets that were not too
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Table 1. DCE Attributes and Levels
Level
Attribute Levels code
Waiting time for scan 2 weeks
4 weeks
6 weeks
2
4
6
Waiting time for results Immediately for 8/10 cases (80%)
Within 2 weeks
−1
1
Procedure Handheld scanner: Patients lie down on a couch; a handheld scanner is moved over the patient’s stomach; patients are able to talk to
doctor/sonographer; patients may be accompanied.
Body scanner: Patients lie down within a scanner which surrounds most of their body (like a tube); patients are not able to talk to
doctor/sonographer; patients may not always have others present
−1
1
Side effects No side effects
Minor side effects in 5/100 cases (5%) (headaches, dizziness, rash)
−1
1
Further procedures No
Possible for 2/10 cases (20%)
−1
1
burdensome for respondents (23). A fractional factorial orthog-
onal design consisting of 72 choice sets was derived using the
fold-over approach in NGENE software (ChoiceMetrics Pty
Ltd, New South Wales, Australia) (24). The design was orthog-
onal for the main effects ensuring the impact of each attribute
level on choice could be independently estimated, near orthog-
onal for all two–way interactions, and level–balanced (i.e., each
attribute level appeared an equal number of times in the design).
The seventy-two choice sets were blocked into 6 survey versions
each including twelve choice sets. Respondents were randomly
allocated to complete one of the six survey versions. For each
version, the first choice set was reversed and repeated as a 13th
choice set, as a consistency check to assess the internal validity
of the data. Responses to the 13th choice set were not included
in the preference model. Thus, each respondent was presented
with thirteen choice sets (e.g., Supplementary Figure 1).
Recruitment and Data Collection
Respondents were recruited from a large internet survey panel
by an independent third party (Qualtrics.com). As panel mem-
bership is voluntary informed consent may be implicitly as-
sumed and formal ethical approval was therefore not required.
The DCE was conducted in the United Kingdom, in February
2014. Using a DCE in a sample of the general population, rather
than in–patients, allows preferences relating to the scan modal-
ity to be identified without the scan outcome potentially biasing
responses. The DCE instrument was administered as an online
survey and respondents were offered an incentive upon com-
pletion of the survey in the form of points that can be collected
and exchanged for cash in certain increments.
It has been demonstrated that confidence intervals for the
parameter estimates start to decrease significantly in sample
sizes of 300 respondents and above (19). Therefore a target
sample size of 500 was selected with the generous sample size
chosen to support a more detailed analysis of preference hetero-
geneity. Stratified sampling was used to recruit the respondents,
i.e. the panel was stratified to match as closely as possible the
demographics of patients with liver conditions based on the UK
incidence of cirrhosis and liver cancers (20). The respondents
were stratified by gender and age (25–34, 35–44, 45–54, 55–
64, 65+ years). The targets for these variables were as follows:
fifty percent of respondents aged 25–44 or 55+ years old, the
remaining 50 percent aged 45–54 years (peak age- incidence);
65 percent male and 35 percent female. Respondents were not
eligible to complete the survey if they were aged below 25
years or if they chose not to answer either the question asking
for their age or for their gender. The online platform (Research
Suite, Qualtrics.com) utilized block randomization to randomly
allocate respondents to one of the six survey versions.
Data Analysis
The choice data were analyzed in NLogit statistical software
(version 5, Econometric Software Inc.) (24) using multinomial
logit (MNL) models for preliminary analyses and then a mixed
logit model (MXL) for the final analysis. The MXL model is
a more generalized analytic approach that relaxes several as-
sumptions associated with the MNL (17). Importantly in this
context, the MXL allows for potential correlation in the multi-
ple choice responses provided by any one individual, and allows
preferences estimated by the model to vary across the individ-
uals in the sample.
The utility function for the choice model was specified as
a linear additive function of the main effects for each attribute
level, as shown Equation 1:
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V (i, j) = β1i jW ScanC + β2i jW Res1 + β3i j Proc1+β4i j SE1
+β5i j F Proc1 (1)
In Equation (1), V(i,j) is the systematic (observed) utility for
individual i associated with choice j (j = Alternative A or Al-
ternative B); β1–5 are the beta coefficients (also referred to as
preference weights, marginal utilities or part worths) associated
with each attribute level; and WScanC, WRes1, Proc1, SE1,
FProc1 are the attribute levels, as defined in Table 1.
Models were initially estimated with all attribute levels ef-
fects coded (23). Preliminary analysis using anMNLmodel con-
firmed the main effects for the attribute “waiting time for scan”
were linear; therefore all models were specified with this at-
tribute coded as a continuous attribute. Preliminary MNL anal-
yses suggested none of the two–way interactions between the
attributes significantly explained choice; therefore, they were
not included in the final MXL model specification.
All attribute levels were specified as random parameters in
the MXL model, and were assumed to follow a normal dis-
tribution. Respondents’ characteristics (Table 2) were entered
into the MXL model as potential predictors of preference het-
erogeneity around the mean parameter for each attribute level,
and then removed using a backward-step approach if they did
not explain preference heterogeneity at the 20 percent and then
10 percent significance level. All characteristics explaining het-
erogeneity at the 10 percent level for at least one attribute were
retained in the final MXL model. A sensitivity analysis ex-
plored the stability of findings to the removal of inconsistent
responders, by estimating an MXL model including only the
sub–group of responders who provided a consistent response
to the repeat choice task. All preliminary MXL models were
estimated using 50 Halton draws, the final model was specified
using 1,000 Halton draws.
RESULTS
Sample Characteristics
Data from a total of 504 respondents were available for analysis
before all age and gender quotas were filled. A total of 708
surveys were started with 204 surveys returned incomplete. The
completion rate was therefore 71.2 percent. A similar number of
respondents (between eighty-two and eighty-five respondents)
completed each survey version.
A summary of the respondent characteristics is provided in
Table 2. Consistent with the stratified approach to sampling, all
respondents were over 25 years old, 50 percent of the sample
were aged 45–54 years old, there were more males (65.1 per-
cent) than females (34.9 percent) in the sample. All education
categories were represented, the category with the most respon-
dents (32.1 percent) was the highest level of education being
undergraduate university. The majority of respondents were in
full–time work (52.0 percent).
There were 475 previous US, CT, or MRI scans reported
(these categories were not mutually exclusive). The majority of
respondents had not been admitted to hospital in the past 12
months (58.3 percent) and had spent no time in hospital as an
inpatient in the last five years (52.6 percent). Few respondents
(9.3 percent) reported a history of liver disease.
DCE Analysis
The majority of respondents (n = 424, 84.1 percent) provided
a consistent response to the repeated choice task. The sensitiv-
ity analysis comparing the model estimates for all responders
to those based on the sub–group of consistent responders indi-
cated the mean coefficients for the attribute levels were similar
for both models in terms of significance, direction of preference
and relative size, and were highly correlated (Supplementary
Figure 2; R2 = 0.905). Therefore, the findings are not consid-
ered to be sensitive to the inclusion/exclusion of inconsistent
responders. All responders were retained for the analysis.
A total of 6,048 choice observations were included in the
preference model (12 choices each from 504 respondents, ex-
cluding the repeated consistency task). All characteristics tested
except whether a respondent was employed explained prefer-
ence heterogeneity (p  .10) in the preliminary MXL model
and were therefore included in the final MXL model. The fi-
nal model with covariates explained a greater proportion of the
choice variance (AIC/N 0.985) than the MXL model without
covariates (AIC/N = 0.998) and represented a substantial im-
provement in fit over anMNLmodel (AIC/N= 1.047). The final
model had a pseudo R2 of 0.305, representing an acceptable fit
for a discrete choice model. The final model is presented in
Supplementary Table 3 (parameters significant at the 5 percent
level only; with all model parameters presented in Supplemen-
tary Table 2).
The coefficients in the MXL model indicate the relative
strength of preference or “preference weight” for improvements
in the attributes (characteristics) of a scan. All attributes were
statistically significant in impacting choice between different
scan alternatives at the 1 percent level or higher, and coefficients
were in the anticipated direction (Supplementary Table 3). On
average, respondents preferred shorter waiting time for the scan
and for results, the procedure to be undertaken with a handheld
scanner on a couch instead of within a body scanner, no side ef-
fects, and no follow–up scans. However, these were the average
respondent preferences, and substantial heterogeneity was ob-
served in the strength of preference around the mean preference
weights for the attribute levels across the sample.
There were several characteristics that significantly ex-
plained the variation in preference between respondents for
each attribute (p  .05: Supplementary Table 2; with a sum-
mary of statistically significant effects presented in Table 3).
Younger respondents (34 years) and those with a history of
hospital admission(s) were less averse to waiting for a scan;
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Table 2. Respondent Characteristics for DCE (N = 504)
Characteristic Category N (%)
Agea 25–34 63 (12.5)
35–44 53 (10.5)
45–54 252 (50.0)
55–64 77 (15.3)
65 and over 59 (11.7)
Gender Male 328 (65.1)
Education Primary school 2 (0.4)
Some secondary school 9 (1.8)
Completed secondary school 139 (27.6)
Some additional training (apprenticeships) 130 (25.8)
Undergraduate university 162 (32.1)
Postgraduate 60 (11.9)
Prefer not to answer 2 (0.4)
Occupational status Not working 88 (17.5)
Full–time 262 (52.0)
Part–time 61 (12.1)
Temporary leave 3 (0.6)
In training (apprentice) 0 (0.0)
Student 4 (0.8)
Retired 86 (17.1)
Previous scanb US 192 (38.1)
MRI 185 (36.7)
CT 98 (19.4)
Last admitted to hospital This month 8 (1.6)
1–3 months 27 (5.4)
>3–6 months 22 (4.4)
>6–12 months 47 (9.3)
>12 months 294 (58.3)
Never 106 (21.0)
No. of weeks in hospital (past 5 years) No time in last 5 years 265 (52.6)
Less than 1 week 126 (25)
1–2 weeks 59 (11.7)
>2–4 weeks 27 (5.4)
>4–6 weeks 8 (1.6)
>6–8 weeks 11 (2.2)
>8–10 weeks 3 (0.6)
10+ weeks 5 (1.0)
History of liver disease No history 457 (90.7)
a Only respondents over 25 years were eligible to complete the DCE.
b Does not add to 100% as some answers were other/don’t know/none. Categories were not mutually
exclusive.
whereas, respondents with a higher education level, better qual-
ity of life (QoL; SF-6D Index score >0.7), or history of previ-
ous ultrasound imaging were more averse to waiting for a scan.
Respondents with a history of hospital admission(s) were less
averse to waiting for results. Males were less averse to having a
scan in a body scanner; whereas, respondents with better QoL
were more averse to having a scan in a body scanner. Older re-
spondents (65 years) were less averse to suffering minor side
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Table 3. Summary of Direction of Preference and Preference Heterogeneity for the Five Attributes
On average, respondents Respondents who were Respondents who were
preferred (p 0.05) less averse (p 0.05) more averse (p 0.05)
Shorter waiting time for scan Less averse to wait:
• Younger (34 years)
• History of hospital admission(s)
More averse to wait:
• Higher education level
• Better QoL (SF-6D > 0.7)
• History of previous ultrasound imaging
Shorter waiting time for results Less averse to wait:
• History of hospital admission(s)
To avoid body scanner (i.e. preferred handheld scanner) Less averse to body scanner:
• Males
More averse to body scanner:
• Better QoL (SF-6D > 0.7)
No side effects Less averse to minor side effects:
• Older (65 years)
More averse to minor side effects:
• Better QoL (SF-6D > 0.7)
No further procedures More averse to further procedures:
• Better QoL (SF-6D > 0.7)
effects than younger respondents; whereas, respondents with
better QoL were more averse to suffering side effects. Respon-
dents with better QoL were more averse to requiring possible
further procedures.
In addition, some further respondent subgroups appeared
to have different preferences for some of the scan characteris-
tics (p  .1); although, these effects failed to reach statistical
significance at the conventional 5 percent level (Supplementary
Table 2). Older respondents (65 years) and males appeared
less averse to waiting for results; younger respondents ( 34
years) appeared less averse to having a scan in a body scan-
ner; respondents who had no history of imaging appeared less
averse to suffering minor side effects, and respondents with a
history of hospital admission(s) appeared slightly less averse to
requiring possible further procedures.
A substantial amount of heterogeneity still remained, even
after including these characteristics in the model (indicated by
the significant standard deviations for all random parameters;
p  .01). This was particularly the case for the type of proce-
dure (handheld scanner on couch versus body scan). For this
attribute, the standard deviation was relatively high compared
with the mean sample preference, indicating that the direction
of preference was likely reversed for some respondents; that
is, a minority of respondents preferred the body scan over the
handheld scanner.
Willingness to Wait For Preferred Scan Characteristics
The estimated averagemarginal time that respondentswerewill-
ing to wait to gain an improvement in an imaging characteristic
were estimated as a ratio of the relevant mean parameter weights
from the MXL model (Supplementary Table 3). Confidence in-
tervals were estimated using the Delta method.
The average respondent was willing to wait almost an ad-
ditional 2 weeks to have the scan if it resulted in avoiding side
effects, approximately 1.5 weeks to avoid further procedures or
to be likely to be told the results immediately, and almost 1 week
to have the scan performed on a couch with a handheld scan-
ner rather than inside a body scanner (Figure 1; Supplementary
Table 1).
DISCUSSION
Overall, the findings of this study suggest that an individual
belonging to a general population sub–group most likely to re-
quire imaging to characterize focal liver lesions would on aver-
age prefer CEUS over contrast-enhancedMRI/CT. Respondents
preferred shorter waiting times for the scan and results, the ul-
trasound scanning process compared with the body scanner and
no side effects, all of which are associated with CEUS as op-
posed to CE-MRI/CT. However, there was a preference for not
having follow–up scans. Repeated imaging is associated with
the CEUS process in around 20 percent of cases (as reported in
the clinician interviews) whereas, a repeated scan is likely to be
required less frequently following an initial contrast–enhanced
MRI or CT scan (11). Nevertheless, the strength of preference
for avoiding a follow–up scan was relatively small, as com-
pared to the collective preference for the other characteristics
associated with CEUS. Research exploring patient experience
of CEUS is absent from the literature and few studies have ex-
amined patient preferences comparing imaging modalities (13);
to–date no studies have used a DCE to measure preferences for
CEUS, CE-MRI, or CE-CT. Therefore, these findings provide
valuable insight into preferences, and the factors that influence
preference between CEUS and CE-MRI or CE-CT.
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Figure 1. Mean marginal willingness to wait for improvements in imaging characteristics. Error bars represent 95 percent confidence intervals.
The attributes in the DCE (waiting time for scan, waiting
time for results, type of procedure, side effects, and further
procedures) all significantly explained preferences in the direc-
tion anticipated by imaging clinicians (15). Previous research
suggests that patients wish to hear the scan results soon after
the procedure (14). Similarly, van Dongen et al. (2011) inves-
tigated preferences for diagnostic imaging of the uterine cavity
and found that short waiting time influenced patient preferences
for a particular scanningmodality (19). The importance of short
waiting time for results on patient preference is supported by
the current findings.
These results are also of potential significance to clinical
practice. Although patient choice of imaging modality is lim-
ited within the UK health system (15), patient preference for
the immediacy of scan results, fewer side-effects, and other fea-
tures associated with the ultrasound modality may help both
to facilitate patient–clinician interactions, and inform clinical
decision-making processes regarding scan modalities, particu-
larly given that CEUS has been shown to be as diagnostically
effective as CE-MRI and CE-CT (25). Therefore where clini-
cally warranted, that is where other imaging modalities would
not add to the diagnostic picture, and indeed would potentially
lead to patient anxiety and distress CEUS could be offered as
an alternative scan option. Overall, the findings suggest that
the majority of patients requiring a scan to diagnose focal liver
lesions are likely to prefer CEUS over CE-MRI or CE-CT, es-
pecially if CEUS can provide shorter waiting times for the scan
or results or a reduction in the chance of suffering minor side
effects. This would suggest that if only one modality can be
provided, then based on a consideration of patient preference
alone, CEUS ismost likely to be the optimal modality. However,
the substantial variation in preferences suggests that this may
not always be the case. Patients who are particularly averse to
further procedures and who may be less averse to a body scan-
ner procedure type may prefer CE-MRI or CE-CT. The study
findings make it difficult to identify exactly what patient sub-
group this may be. Whereas male patients may be less likely
to be averse to a body scanner, respondents with better QoL
were both less likely to be averse to further procedures but also
more likely to be averse to a body scanner. Younger respon-
dents or those with a history of hospital admission(s) were less
averse to waiting and so may also be more willing to accept
CE-MRI or CE-CT. Overall, the substantial variation observed
in respondent preference also highlights the need to discuss
the comparative advantages of available imaging modalities
with individual patients if a choice of alternative modalities is
available.
LIMITATIONS
In common with other DCE studies, the findings of this DCE
assume that the choices respondents say theywouldmakewould
actually be made in practice, were they to require liver imag-
ing. However, the careful pilot testing and similarity between
preferences estimated by the DCE and clinician expectation
of preferences study provides some reassurance of validity in
this regard. The preferences elicited relate only to the attributes
included in the study; there may be other imaging characteris-
tics (e.g., exposure to ionizing radiation) that may be relevant
for some consumers but were not included in the choice. The
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number of attributes and levels was kept to those deemed likely
to be most important for consumers in the foundation work
developing the DCE, to minimize respondent burden (23).
The findings identified substantial variation around the char-
acteristics of preferred scanning modalities, some of which re-
mained unexplained in the model. Further exploration to iden-
tify specific patient sub-groups whomight prefer the body scan-
ner modality and why is of particular interest. Although the
study sample was comparatively large for a health-related DCE
(17), a larger study including a qualitative research component
could explore this heterogeneity further. This study also elicited
preferences under the assumption that all alternative imaging
modalities are of similar effectiveness, in terms of longer–term
patient–relevant health outcomes such as QoL and survival.
Whereas the current evidence base suggests this is largely the
case, it may not be so for selected indications (1). We did not
explore whether health outcome would influence consumer de-
cisions, if indeed a longer term difference in comparative health
outcome were to be associated with CEUS. This is an avenue
for future research.
CONCLUSION
This study extends what is known about the factors influencing
patient preferences of imaging modalities, and adds new re-
search specifically relating to CEUS as recommended in NICE
Diagnostics Guidance 5 (1). This research should help inform
the guideline update, particularly around the design and pro-
vision of clinical services to incorporate CEUS as an imaging
modality for diagnosing focal liver lesions and guidance for
clinicians in respect of the diagnostic options available. Fur-
thermore, it provides some insights for health professionals into
the likely preferences of their patients related to alternative scan
modalities. Whereas CEUS appears to be preferred in general,
the variation in preferences observed highlights the importance
of discussing individual patient choice, where more than one
modality is available. Future research should explore the is-
sues identified in the study, such as, understanding how and in
which direction preferences change in different sub–groups of
the patient population. Research should examine the underly-
ing reasons for the sub–group differences such as patient cir-
cumstances, previous experience, and, knowledge of diagnostic
scanning procedures.
It appears that clinicians are intuitively aware of consumer
preference and the likely direction these preferences take (15).
This research demonstrates that consumer preference generally
favors CEUS over CE-CT or CE-MRI for the diagnosis of liver
lesions; however, healthcare providers need to consider how
they will implement CEUS in their diagnostic pathway and how
to routinely incorporate patient choice into clinical care.
SUPPLEMENTARY MATERIAL
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